Top Banner
Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant Division Kyoto University Hospital Kyoto Japan Expandidng the pool: Impact of Living Donor and Split Liver Transplantation Kyoto Japan June 9 2004
40

Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Mar 15, 2020

Download

Documents

dariahiddleston
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Living Donor Liver Transplantation for Fulminant Hepatic Failure

Hiroto Egawa M.D.Organ Transplant DivisionKyoto University HospitalKyoto Japan

Expandidng the pool: Impact of Living Donor and Split Liver TransplantationKyoto Japan June 9 2004

Page 2: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Liver Transplantation for FHF

• FHF is rapidly progressive and irreversible• Need for liver transplantation is urgent• It is difficult to obtain grafts in a timely

manner from cadaveric donors• The death rate of patient awaiting for liver

transplantation is as high as 40% or 62%.

Page 3: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Rare cadaveric donors in Asia

>80% mortality in the absence of liver trasnplantation

Almost hopeless wait Living Donor Liver Transplantation

Page 4: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Living–related Liver Transplantation in FHFMatsunami et al. Lancet 1992;340:1411

•15-year-old boy of 48 kg•Acute liver failure by drug reaction•Left lobe graft from his father•51% of SLV

Page 5: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

LDLT for FHF

Advantage– Availability of graft

• short waiting time • timely transplantation

– Good quality of a graftfrom a healthy donor

Page 6: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

LDLT for FHF

Disadvantage– Short time to decide the donation– Short time to evaluate donor candidates– Donor complications– Complex surgery – Recipient complications– Possible small for size graft

Page 7: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Offer 1st interview and inform Family of a recipientFamily of donor candidates

Medically acceptable recipient &Definite voluntary willingness of a donor

Recipient transfer& further evaluation

Medical and psychological donor evaluation

Separate donor interview

2nd interview of recipient family & donor

Transplantation

Secure & quick

Page 8: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Urgent Living-Donor EvaluationMedical

Physical ex. &laboratory data

Blood type (30min)CBC, coagulation, chemistry (30min) Infection (2hr) HLA (2hr)Occult blood of stool, Urine analysis (5min)

RadiologyAbdominal & chest X-p (5min)US scleening (20 min) CT scan (15min) Check steatosis &

Anatomy &Volumetry

Cardio-pulmonaryfunction check ECG, UCG, spirometry

PsychologicalInterview by psychiatrist

1hr

Decision

Page 9: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Non-alcoholic Steato-hepatitisNo alcoholic historyNo other etiology

Risk factorsdiabetes, hyperlipidemia, obesity, hypertension

Symptoms no specific symptoms and liver failure with chirrosis

Physical signshepatomegaly

Pathologysteatosis and fibrosis

Incidenceunknown in Japan, increasing

Page 10: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Preoperative Assesment of Steatosiswith CT Scan

Liver / Spleen ratio ofCT value #1/ #3: 53.9 / 58.9 = 0.91#2/ #3 : 58.3 / 58.9 = 0.98

Safety value > 1.2Marginal value 1.0-1.2Risky value <1.0

Steatosis >> excise, diet >> re-assessment

But, how should we do in an urgent case ?

Page 11: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Strategy for Possible Steatosis in an Urgent Case

• High risk donor: alchohol, BMI >28 • Suspected by radiology: US, CT

BMI (Rinella. Liver Transplantation 2001;5:409)

Evaluation by CT density: liver / spleen ratio (LSR)

LSR<1.0 LSR >1.0

Abnormal LFT Normal LFT

accept

Liver biopsy

reject

HbA1C, HOMA-IRNo OK

No OK

Page 12: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

metabolic

PSC

PBC

BA

reTx

tumor

LC

FHFcholestatic

tumorLC

metabolic

FHF

othersothers82 cases

Pediatric Adult

Indication for Living Donor Liver Transplantation in Kyoto

Page 13: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

100

50

0 5 10

metabolic

cholestatic

Indication and Patient Survival in Children

(years)

tumor

fulminantLiver cirrhosis

%

Page 14: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

100

50

0 5

metabolic

cholestatic

Indication and Patient Survival in Adults

(%)

(years)

tumor

fulminant

Liver cirrhosis

Page 15: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Etiology of FHF

<1 y.o. 1~18 y.o.

Unknown (15)

HBV (1) HSV (1)

≥18 y.o.

Unknown (15)

HBV (3)Heat stroke(1)

Unknown (22)

HBV (16)

AIH (2)HAV (2)

Drug induced (3)

Chrome poison (1)

Page 16: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Donor

<1 y.o. 1~18 y.o. ≥18 y.o.

Father (8)

Mother (8)

Father (8)Mother (8)

Father (9)

Mother (3)Sibling (16)

Child (9)

Spouse (8)Uncle (1)

Ground mother (1)

Page 17: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Blood Type Combination

<1 y.o. 1~18 y.o.

Identical (10)

Compatible (3)

Incompatible (4)

≥18 y.o.

Identical (13)

Compatible (6)

Identical (35)

Compatible (9)Incompatible (2)

Page 18: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Graft TypeReduced-mono (2)

Mono (3)

Lateral (12)

<1 y.o.

Left (4)

Mono (1)

Lateral (9)

Right (3)

APOLT (2)

1~18 y.o. ≥18 y.o.

Left (6)Ext.Lat. (1)

Right (34)

APOLT (4)

Page 19: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Recipient Age and Patient Survival100

50

05 10

%

years

<1years

1-18 years

>18 years

Page 20: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Impact of Recipient Age• Inferior outcomes of the less-than-1-year-old children

– Farmer DG, et al. Ann Surg 2003;237:666– Bonatti H, et al. Transplant Proc 1997;29:434– Noujaim HM, et al. J Pediatr Surg 2002;37:159

Technical difficulty

Rash deterioration Donor scarcity

Vascular thrombosis

SepsisHaemorrhageMOF

Low incidence of ACRbut

Page 21: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

LDLT for FHF in Children

• 8patients(Age:3 mo-11years)• Etiology: drug induced (2), idiopathic (6)• Outcomes

– 3 death in patients with idiopathic etiology– Causes of death

• Recurrence of acute hepatitis in the 3 months old child• Refractory rejection in the 8 months old child

Lie CL et al. Liver Transplantation 2003;9:1185

Page 22: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Result of LDLT for FHF in Children <1y.o.-Kyoto Experience-

Etiology outcome Causes of death

HBV(1) aliveHSV(1) alive

unknown(15) alive (4) (normal LFT [1] and waiting for re-Tx [2])dead (11) recurrent hepatitis (5)

refractory ACR (1)chronic rejection (1)EBV hepatitis (1)MOF after Rota-virus infection (2)HAT (1)

Page 23: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Result of LDLT for FHF in Children <1y.o.-Kyoto Experience-

Etiology Biopsy findings

HBV (1) no biopsyHSV (1) no biopsy

unknown (15) moderate ACR (4)severe ACR (7)chronic rejection (1)hepatitis (7)massive necrosis (4)

Page 24: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

A Case of FHF 5 months old girl, 7.8 kg, unknown etiologyDonor: mother, identical blood type

severe ACR with hepatocyte dropout, simulating “recurrent fulminant hepatitis

moderate ACR with lobulainflammation

Day 12 Day 24

Page 25: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

LDLT for FHF with unknown etiologyin Children <1y.o.

• Poor outcomes• Strong immunosuppression is required• No strategy for recurrent hepatitis

Page 26: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

LDLT for FHF in KyotoComa grade

II (12)

III (19)

IV (13) Hyperacute(9)

Acute (21)

Subacute(12)

Type

Hoofnalge 1991

hyper acute subacute

jaundice encephalopathy7d 28d

Adult cases

Page 27: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Neurological Death after LDLT

• Reported incidence: 4 ~ 11%• Kyoto Experience

– Incidence: 5%– All adult patients– GBWR: 0.73 ~ 1.24%– Preoperative coma grade: III (1), IV (3)

Page 28: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

How much volume do we needfor adult patients with FHF?• Left lobe :

– 23%-54% SLV• Nishizaki et al. Surgery 2002;131:182

– >35% • Miwa et al. Hepatology 1999;30:1521

• Right Lobe – 40% and more is favorable

• Liu et al. British J Surgery 2002;89:317

• Right or left or APOLT ?

Page 29: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

100

50

0

%

Years

Left Lobe

Right Lobe

51 2 3 4 6 7

APOLT

Graft Type and Patient Survival

Page 30: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

GBWR and Graft Type

0

0.2

0.4

0.6

0.8

1

1.2

1.4

Right Lobe Left Lobe APOLT

GBWR = graft weight/recipient weight x100 (%)

Page 31: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

GBWR and Patient Survival100

50

0 51

%

Years

GBWR < 0.8%

GBWR >1.0%

GBWR 0.8-1.0%

2 3 4 6 7

P<0.05

Page 32: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

How much volume do we needfor adult patients with FHF?

• There is no difference between left lobe and right lobe when the graft volume is enough.

• The safe limit is GBWR of 0.8.• Grafts with GBWR of 0.8 should be used

even in APOLT .

Answer

Page 33: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Risk Factors in Adults-Kyoto Experience-

• Preoperative factors– Other organ dysfunction

• Renal dysfunction: Cre>2.0, with dialysis• Respiratory dysfunction: on ventilator• Pancreatitis

– Preoperative steroid administration > 20 days– MELD > 25 (p=0.054)

• Operative factors– Small for size: GBWR < 0.8

Page 34: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Small-for-size Syndrome

• Prolonged cholestasis

• Coagulopathy

• Massive ascites

• Gastrointestinal bleeding

• Renal dysfunction

Page 35: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Strategy for Small for Size Graft

• Monitoring PV pressure < 20cmH2O

• Surgery– Outflow wide anastomosis

reconstruction of HVs draining to MHVright lobe graft with MHV

– Inflow splenic artery ligationporto-caval shunt

Page 36: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Small-for-size partial liver graft in an adult recipient; a new transplant technique

O.Boillot, et.al., The LANCET; vol.359 (2002)

banding

PC shunt

Page 37: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

A Case of Heat Stroke• Recipient

– 16y.o. boy– Heat stroke with liver &

kidney failure– Come grade IV– 79kg in body weight

• Donor– Patient's mother– 51kg in body weight

• GBWR: 0.62 (496g)

Page 38: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Effect of Inflow Modurationfor Small for Size

0

500

1000

1500

2000

2500

3000

3500

4000

4500

-5 0 5 10 15 20 25 30 35 40 45 50 55 60 65

0

5

10

15

20

25

POD

PT

ALT

T-Bil

ALT T-Bil, PT(sec)

r-PVRecipient left PV

Partial porto-caval shunt

Page 39: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Musts in LDLT for FHF• Aim 1: Timely LDLT

– Offer to LDLT center ASAP– Inform family about an option of LDLT ASAP– Evaluate donor candidate quickly

• Aim 2: Donor safety & ethics– Inform donor risks as well as recipient benefits– Do not rush donor candidates to decide organ donation – Evaluate donor candidate without omission – Secure residual liver volume >30%

• Aim 3: Enough graft & residual liver volume– Choose graft type with GBWR > 0.8– Choose appropriate procedures in case of small for size graft

Page 40: Living Donor Liver Transplantation for Fulminant Hepatic Failure · 2013-05-13 · Living Donor Liver Transplantation for Fulminant Hepatic Failure Hiroto Egawa M.D. Organ Transplant

Save recipient

Donor safety

Donor Evaluation in LDLT for FHF